Last 48 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -567.68 | — | 62.20 | 26.15 | — | — | 11.17 | 18.60 | 25.68 | 31.95 | 37.42 | 47.47 | 219.14 | 105.33 | 74.72 | 93.50 | — | — | 138.12 | 31.09 | — |
| — | — | +456.7% | +40.6% | — | — | -70.1% | -60.8% | -88.3% | -69.7% | -49.9% | -49.2% | — | — | -45.9% | +200.8% | — | — | -53.7% | -85.2% | — | |
| P/S Ratio | 2.96 | 2.83 | 2.81 | 3.64 | 3.35 | 3.35 | 3.27 | 4.66 | 4.32 | 4.65 | 5.80 | 6.71 | 7.16 | 7.27 | 7.10 | 7.92 | 8.95 | 7.78 | 7.28 | 7.23 | 9.01 |
| — | -15.4% | -14.3% | -21.8% | -22.4% | -27.9% | -43.5% | -30.5% | -39.6% | -36.1% | -18.4% | -15.4% | -20.1% | -6.5% | -2.4% | +9.5% | -0.7% | -10.1% | -5.6% | +1.0% | +0.8% | |
| P/B Ratio | 1.82 | 1.86 | 1.76 | 1.80 | 1.93 | 1.72 | 1.79 | 2.40 | 2.28 | 2.56 | 3.12 | 3.43 | 3.74 | 3.45 | 3.53 | 4.06 | 4.18 | 3.44 | 3.45 | 3.42 | 3.80 |
| — | +8.1% | -2.0% | -25.0% | -15.6% | -32.9% | -42.6% | -30.1% | -38.9% | -25.9% | -11.6% | -15.4% | -10.7% | +0.3% | +2.5% | +18.6% | +10.0% | +3.8% | -5.5% | +2.3% | -3.5% | |
| P/FCF | 19.41 | 18.16 | 19.94 | 13.98 | 49.77 | 7.76 | 16.07 | 22.03 | 19.54 | 17.30 | 42.58 | 338.14 | — | 37.68 | 89.28 | — | — | 32.28 | 137.76 | — | — |
| — | +133.9% | +24.1% | -36.5% | +154.7% | -55.1% | -62.3% | -93.5% | — | -54.1% | -52.3% | — | — | +16.7% | -35.2% | — | — | -30.1% | +114.3% | — | — | |
| EV / EBITDA | 20.21 | 77.86 | 17.31 | 17.78 | 27.70 | — | 8.63 | 13.66 | 17.00 | 25.93 | 28.31 | 38.32 | 114.64 | 76.61 | 47.54 | 54.64 | 92551.42 | 179.39 | 62.11 | 23.55 | — |
| — | — | +100.5% | +30.1% | +63.0% | — | -69.5% | -64.3% | -85.2% | -66.2% | -40.5% | -29.9% | -99.9% | -57.3% | -23.5% | +132.0% | — | — | -39.3% | -65.1% | — | |
| EV / EBIT | 19.05 | — | 28.95 | 16.62 | — | — | 8.48 | 13.95 | 18.30 | 25.08 | 30.64 | 40.68 | 189.66 | 94.75 | 58.01 | 80.27 | — | 1447.10 | 103.37 | 28.10 | — |
| — | — | +241.2% | +19.2% | — | — | -72.3% | -65.7% | -90.4% | -73.5% | -47.2% | -49.3% | — | -93.5% | -43.9% | +185.7% | — | — | -53.3% | -78.8% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.1% | 80.0% | 79.5% | 74.6% | 66.3% | 82.0% | 81.8% | 79.7% | 81.8% | 74.7% | 81.7% | 80.7% | 79.0% | 78.0% | 78.1% | 77.3% | 76.3% | 77.0% | 76.9% | 77.5% | 73.4% |
| — | -2.4% | -2.8% | -6.4% | -19.0% | +9.7% | +0.2% | -1.3% | +3.5% | -4.2% | +4.6% | +4.4% | +3.6% | +1.3% | +1.5% | -0.2% | +4.0% | +3.1% | +3.0% | +2.9% | +1.8% | |
| Operating Margin | 16.6% | -8.0% | 11.2% | 16.9% | 9.1% | -6.0% | 33.5% | 30.0% | 21.6% | 15.3% | 16.9% | 13.6% | 2.2% | 5.3% | 11.0% | 10.5% | -4.6% | -0.5% | 7.3% | 26.4% | -14.6% |
| — | -33.2% | -66.6% | -43.7% | -58.0% | -139.4% | +98.3% | +120.4% | +881.6% | +190.9% | +53.6% | +30.3% | +148.3% | +1197.8% | +50.2% | -60.4% | +68.9% | +96.3% | +215.3% | +412.3% | -47.7% | |
| Net Margin | 10.8% | -12.0% | 4.5% | 13.8% | -5.3% | -4.0% | 29.1% | 24.9% | 16.7% | 14.2% | 15.1% | 13.7% | 3.2% | 6.9% | 9.4% | 8.5% | -0.0% | -1.3% | 5.2% | 23.3% | -12.9% |
| — | -202.6% | -84.5% | -44.7% | -131.9% | -127.8% | +93.6% | +82.4% | +430.3% | +104.8% | +59.9% | +60.3% | +6909.9% | +627.7% | +81.7% | -63.3% | +99.6% | +85.3% | +100.9% | +550.8% | -363.3% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.9% | -2.0% | 0.7% | 1.7% | -0.8% | -0.5% | 4.1% | 3.2% | 2.3% | 2.0% | 2.1% | 1.8% | 0.4% | 0.8% | 1.2% | 1.1% | -0.0% | -0.1% | 0.6% | 2.8% | -1.4% |
| — | -283.9% | -82.4% | -47.1% | -134.0% | -125.7% | +96.7% | +83.3% | +445.4% | +137.7% | +74.3% | +61.1% | +7763.0% | +669.1% | +90.9% | -60.7% | +99.6% | +82.9% | +101.9% | +564.2% | -350.6% | |
| ROA | 4.8% | -1.1% | 0.4% | 1.3% | -0.6% | -0.4% | 3.3% | 2.6% | 1.8% | 1.5% | 1.5% | 1.3% | 0.3% | 0.6% | 0.9% | 0.8% | -0.0% | -0.1% | 0.5% | 2.0% | -1.0% |
| — | -158.5% | -86.6% | -50.4% | -133.9% | -126.8% | +114.2% | +103.2% | +502.6% | +151.5% | +78.3% | +62.8% | +7782.1% | +665.5% | +90.3% | -60.3% | +99.6% | +82.6% | +105.0% | +571.6% | -362.5% | |
| ROIC | 7.4% | -0.6% | 1.1% | 1.8% | 1.1% | -0.6% | 3.9% | 3.1% | 2.3% | 1.6% | 1.7% | 1.2% | 0.2% | 0.4% | 0.9% | 0.9% | -0.4% | -0.0% | 0.6% | 2.1% | -1.0% |
| — | +1.7% | -71.4% | -43.1% | -51.6% | -140.7% | +131.4% | +154.3% | +1018.4% | +260.4% | +75.5% | +34.2% | +154.6% | +1301.1% | +59.4% | -56.8% | +64.2% | +95.7% | +215.5% | +418.0% | -39.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.67 | 0.66 | 0.23 | 0.11 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.21 | 0.22 | 0.22 | 0.22 | 0.23 | 0.23 | 0.24 | 0.24 | 0.24 | 0.25 | 0.26 |
| — | +571.4% | +563.5% | +123.0% | -0.9% | -10.4% | -51.8% | -51.9% | -51.9% | -50.2% | -9.0% | -7.9% | -6.8% | -6.4% | -5.7% | -5.5% | -7.0% | -6.3% | -5.5% | -4.9% | -3.5% | |
| Debt / EBITDA | 1.05 | 86.60 | 20.15 | 9.86 | 6.44 | — | 2.04 | 2.45 | 3.26 | 4.53 | 7.48 | 9.47 | 26.67 | 19.49 | 12.02 | 12.31 | 20630.08 | 48.75 | 16.95 | 6.62 | — |
| — | — | +885.8% | +302.8% | +97.7% | — | -72.7% | -74.2% | -87.8% | -76.7% | -37.7% | -23.1% | -99.9% | -60.0% | -29.1% | +85.8% | — | — | -39.4% | -67.7% | — | |
| Current Ratio | 5.21 | 2.44 | 2.39 | 5.81 | 5.21 | 4.83 | 5.56 | 5.52 | 5.33 | 4.27 | 3.05 | 2.74 | 2.51 | 2.54 | 4.94 | 4.75 | 4.67 | 5.15 | 5.42 | 4.88 | 4.16 |
| — | -49.4% | -57.1% | +5.2% | -2.2% | +13.0% | +82.1% | +101.2% | +112.0% | +68.1% | -38.2% | -42.2% | -46.2% | -50.7% | -8.8% | -2.7% | +12.3% | +14.7% | +1.9% | -8.3% | -12.5% | |
| Quick Ratio | 3.50 | 1.32 | 1.32 | 4.20 | 3.50 | 3.10 | 3.60 | 3.49 | 3.29 | 2.62 | 1.95 | 1.70 | 1.57 | 1.65 | 3.31 | 3.21 | 3.15 | 3.54 | 3.69 | 3.28 | 2.74 |
| — | -57.2% | -63.5% | +20.3% | +6.2% | +18.0% | +85.2% | +105.6% | +109.7% | +58.7% | -41.2% | -47.2% | -50.2% | -53.3% | -10.4% | -1.9% | +15.1% | +16.6% | -0.6% | -10.5% | -17.9% | |
| Interest Coverage | 45.27 | -1.37 | 1.97 | 10.44 | -8.77 | -9.21 | 112.19 | 84.16 | 66.70 | 46.30 | 37.97 | 30.76 | 4.07 | 12.03 | 19.86 | 16.33 | -4.01 | 0.59 | 10.03 | 36.26 | -16.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BMRN stock.
BioMarin Pharmaceutical Inc.'s current P/E is -567.7x. The average P/E over the last 2 quarters is 44.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioMarin Pharmaceutical Inc.'s current operating margin is 16.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioMarin Pharmaceutical Inc.'s business trajectory between earnings reports.